Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and macrophages that secrete high amounts of inflammatory cytokines. HLH occurring after SCT is difficult to diagnose. It is characterized by severe clinical manifestations and high mortality. Despite current therapeutic approaches, outcomes remain poor. We analyzed the incidence and risk factors of HLH after SCT and the response to treatment and prognosis of 554 patients with HLH after SCT. The cumulative incidence of HLH after SCT was 4.3% (24/554). Use of etoposide in the conditioning regimen was only factor that reduced HLH after SCT (P ¼ 0.027). All patients who received autologous transplantation were successfully treated. Patients with liver dysfunction (for example, high total bilirubin level, prolonged prothrombin time and high level of fibrinogen degradation products) had a poor response to treatment for HLH. Physicians should be cautious of HLH, while not using etoposide for conditioning regimen.
INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and macrophages that secrete high amounts of inflammatory cytokines.
1 Although HLH is rare in adults, this disease is sometimes observed in children. HLH is usually fatal without treatment. Typical clinical findings include hepatosplenomegaly and prolonged fever that is usually unresponsive to antibiotic therapy. Lymphadenopathy, different kinds of rash, edema and jaundice are less frequent manifestations. Laboratory findings include cytopenias (usually beginning with thrombocytopenia and evolving into severe pancytopenia), hyperferritinemia, elevated transaminases, hypofibrinogenemia, hypertriglyceridemia, hypoalbuminemia and hyponatremia. 1 Additional immunological findings include elevated soluble IL-2 receptor and reduced Natural Killer cell cytotoxicity. Many patients with HLH show signs of disseminated intravascular coagulation. Hemophagocytosis can be absent in the early stages of the disease, 2, 3 but serial BM aspirations may reveal hemophagocytosis later in the course. It is important to note that the diagnosis of HLH does not depend on this morphological finding. HLH occurring after SCT is particularly difficult to diagnose. It is characterized by severe clinical manifestations and high mortality. [4] [5] [6] [7] Despite current therapeutic approaches, outcomes remain poor. The present study analyzed HLH after SCT in patients in Hokkaido prefecture in Japan.
PATIENTS AND METHODS Patients
A total of 554 patients (310 males, 244 females) with different hematological malignancies, solid tumor, metabolic abnormalities and immunodeficiencies underwent SCT between January 2007 and December 2011 at one of 11 institutes in Hokkaido prefecture. The ages of the patients at transplantation ranged from 0 to 73 years (median, 49 years). In all, 167 patients had nonHodgkin's lymphoma, 119 had AML and 76 had ALL. In all, 192 patients had other diseases, including 61 with multiple myeloma, 37 with myelodysplastic syndrome, 20 with solid tumors, 13 with aplastic anemia (AA), 13 with Hodgkin's lymphoma, 11 with CML, 10 with adult T-cell leukemia and 27 with other diseases, including metabolic diseases and immunodeficiency.
Treatment protocols
The origin of the stem cells was as follows: 219 patients received BMT, 232 patients underwent PBSC transplantation and 103 patients received cord blood SCT (CBT). The transplantation donors were related donors in 126 cases and unrelated donors in 240 cases, and autologous transplantation was performed in 188 cases. The conditioning regimen contained BU for 149 patients, etoposide for 183 patients, fludarabine for 208 patients, melphalan for 151 patients, CY for 288 patients and anti-thymocyte globulin for 10 patients. In addition, TBI was used as part of the conditioning regimen for 309 patients. Reduced intensity conditioning SCT was used for 242 patients, and myeloablative conditioning SCT was selected for 312 patients. Prophylaxis for GVHD was performed with cyclosporine for 147 patients, tacrolimus for 208 patients, MTX for 294 patients, methylprednisolone for 22 patients and mycophenolate mofetil for 9 patients. Data were analyzed as of 1 July 2012. Median follow-up time was 12.9 months from SCT. The analysis protocol of the present study was approved by the Institutional Review Board of Sapporo Hokuyu Hospital.
Definition of HLH
We used the criteria for HLH after SCT that were described by Takagi et al.
7
A diagnosis of SCT-HLH required both major criteria, or one major and all four minor criteria. The first major criterion was engraftment failure, delayed engraftment or secondary engraftment failure after SCT, and the second major criterion was histopathological evidence of hemophagocytosis. The four minor criteria were high-grade fever, hepatosplenomegaly, elevated ferritin and elevated serum lactate dehydrogenase. Although progressive cytopenia has formed the backbone of the previous criteria, this criterion was not used in this study, considering the post-SCT setting.
Statistical analysis
A Mann-Whitney U-test or w 2 test was used to compare patients who did versus those who did not develop HLH. Analysis of survival was performed using the Kaplan-Meier method, with differences compared by log-rank test. Cox proportional hazards regression analysis was used for analysis of risk factor of HLH. Statistical analyses were performed using Dr SPSS II for Windows (release 11.0.1J, IBM Japan, Inc., Tokyo, Japan) and R (The R Foundation for Statistical Computing), EZR on R commander (programmed by Y Kanda).
RESULTS

Incidence and onset of HLH
The cumulative incidence of HLH after SCT was 4.3% (24 out of 554). In 24 patients with HPS, 10 patients were male and 14 were female. The age of patients ranged from 4 to 64 years (median, 51 years). HPS occurred in seven patients with non-Hodgkin's lymphoma, four with AML, four with multiple myeloma, three with myelodysplastic syndrome, two with ALL, two with adult T-cell leukemia and one with CML and AA. The origin of stem cell was BMT in 10 patients, PBSC transplantation in 8 patients and CBT in 6 patients. A related donor was used for 3 patients, an unrelated donor was used for 15 patients and 6 patients underwent auto-transplantation. The median time from the date of transplant to onset of HLH was 21 days (range: 10-267 days). The onsets of many patients with HLH were before 30 days after SCT. Patients who had HLH after day þ 30 were 6 out of 24 patients. (day þ 36, þ 41, þ 49, þ 81, þ 175, þ 267). No patient was proved as evident viral infection.
Risk factors for HLH Factors predicting HLH after transplantation were analyzed. Univariate analysis showed no difference in age at transplant, gender, original disease, stem cell source and donor between patients with HLH and no HLH (Table 1 ). In terms of the conditioning regimen, use of etoposide was the only factor that reduced HLH after SCT (P ¼ 0.027). Other therapies, including BU, fludarabine, antithymocyte globulin and TBI, were not related to the occurrence of HLH. Moreover, reduced intensity conditioning or myeloablative condition was not associated with HLH. All three patients who developed complicated HLH despite the use of an etoposidecontaining conditioning had undergone autologous transplantation and were alive at the time of analysis. Occurrence rate of HLH with or without etoposide is shown in Figure 1 . In patients who had undergone SCT without etoposide-containing regimen, incidence of HLH was 6.26% at 1 year after SCT. On the other hand, incidence was 1.66% in those with etoposide-containing regimen, and they were statistically significant (P ¼ 0.0235). Moreover, we performed Cox proportional hazards regression analysis treated death as a time-dependent covariate. This analysis revealed etoposide was statistically significant factor of HLH (P ¼ 0.03472).
We also analyzed by onset day of HLH (early onset: under 30 days after SCT, late onset: over 30 days after SCT). In characteristics of patients, all six patients were female in the late onset group. However, other factors, age, original diseases, stem cell source, conditioning regimen and GVHD prophylaxis, were not different in the two groups. Survival rate of both groups was also not different.
Treatment and outcomes after HLH Treatment analysis was performed using data from 23 patients with HLH (one patient was excluded because of insufficient data). Of these patients, 21 patients were treated with prednisolone or methylprednisolone. Four patients were treated with cyclosporine, two were treated with mycophenolate mofetil, one was treated with etoposide, and one was treated with foscarnet. Two patients underwent re-transplantation for the purpose of treating HLH. We compared factors at diagnosis of HLH between patients who were successfully treated and those who failed treated Etoposide-containing conditioning reduces HLH after SCT R Kobayashi et al (Table 2 ). All patients who received autologous transplantation were successfully treated. Patients with liver dysfunction (for example, high total bilirubin level, prolonged prothrombin time and high level of fibrinogen degradation products) had a poor response to treatment for HLH. Cyclosporine was used in many patients with ineffective results. However, cyclosporine may be used because of resistance to steroid hormone. The survival rate was markedly lower in patients with HLH when compared with those who did not develop HLH (14.5% versus 50.9%, Po0.0001, Figure 2 ). However, there was no difference between survival rate of successfully treated patients and that of failed patients (data not shown).
DISCUSSION
Various studies have described HLH occurring after autologous or allogeneic SCT. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The frequency of HLH after SCT was reported as 4.1% in patients who had undergone autologous and allogeneic SCT 6 and was reported as 16.8% in patients who underwent CBT. 7 In the present study, the cumulative incidence of HLH was 4.3% in all patients and was 5.8% in patients who underwent CBT.
Although some studies have described HLH occurring after SCT, there are few data regarding risk factors for HLH after SCT. Takagi et al. 7 reported that fewer infused CD34 þ cells are a significant risk factor for the development of HLH, and Aldelkefi et al. 6 reported that HLH after SCT was observed in many patients with allogeneic SCT and AA. Unfortunately, multicenter analysis did not include data on CD34 þ cells in our study. Moreover, AA was not risk factor of HLH in our analysis. In our analysis, a conditioning regimen containing etoposide was the only factor associated with a reduction in HLH. Although HLH was observed in more patients who had undergone allogeneic SCT when compared with those who had undergone autologous SCT, this difference did not reach the level of statistical significance. Because etoposide is known as a therapeutic agent for HLH, we think it is very interesting that a conditioning regimen containing etoposide resulted in a reduction in the development of HLH after SCT. 8, 9 The manuscript as risk factor including use of etoposide about HLH was never seen until now. The clear reason conditioning regimen containing etoposide controls development of HLH is not known. Most, but not all, studies suggest that the activated macrophage in patients with HLH is of donor origin.
9,10 Therefore, it is possible that an etoposide-containing condition regimen results in a decrease in macrophage activity, thereby reducing the risk of HLH. Previous studies of HLH after SCT have not included many patients who received an etoposide-containing condition regimen. 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Indeed, none of the patients in the report by Takagi et al. received an etoposide-containing condition regimen. 6 These facts may also serve to support our speculation. Moreover, all three patients who developed complicated HLH despite the use an etoposide-containing condition regimen were alive at the time of analysis. Although all of these patients underwent autologous transplantation, use of etoposide as conditioning agent may improve the effectiveness of treatment for HLH after SCT.
In our analysis, many patients were treated with steroids. Etoposide, which is an effective therapeutic agent for HLH, was used in only one patient. However, treatment was more effective in patients who underwent autologous transplantation and in those with normal hepatic function. In patients who underwent autologous transplantation, HLH were known as good prognosis compared with patients who underwent allogeneic transplantation. However, the grade of liver dysfunction was not known as a prognostic factor in the treatment of HLH. In patients with HLH, Conditioning with etoposide (n =183) 1.66%
Conditioning without etoposide (n =371) 6.26%
Months after SCT Probability Figure 1 . Occurrence rate of HLH with or without etoposide. In patients who had undergone SCT without etoposide-containing regimen, incidence of HLH was 6.26% at 1 year after SCT. On the other hand, incidence was 1.66% in those with etoposide-containing regimen and they were statistically significant (P ¼ 0.0235). Etoposide-containing conditioning reduces HLH after SCT R Kobayashi et al liver dysfunction is likely to progress. Therefore, early diagnosis and treatment is very important in patients with HLH. Although about half of patients had a favorable response to steroids, the overall survival rate in patients with HLH was statistically lower than that for patients without HLH. It is possible that administration of steroids depresses GVHD and thereby increases the risk of relapse.
Some viruses (for example, CMV, Epstein-Barr virus) may be associated with HLH after SCT. Although, none of the patients developed viral infections in the present study, we cannot exclude the possibility that certain viruses are related to the risk of HLH. Regardless, etoposide-containing conditioning regimens will be effective in preventing HLH after SCT.
In conclusion, we find that etoposide-containing conditioning regimens reduce the occurrence of HLH after SCT. Other risk factors for HLH after SCT were not identified. Physicians should be cautious of HLH, while not using etoposide for conditioning regimen.
